Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicenter, Open-label, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Resmetirom in Pediatric Subjects Ages 6-17 Years With MASH With Fibrosis Stage F1-F3

NCT07763015 is registered in ClinicalTrials.gov with Madrigal Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07763015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07763015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicenter, Open-label, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Resmetirom in Pediatric Subjects Ages 6-17 Years With MASH With Fibrosis Stage F1-F3
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2026
Completion date
July 31, 2029
Enrollment
61 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mash, mash - metabolic dysfunction-associated steatohepatitis